Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 901–1,000 of 1,640
Epigenetic modulation: Research progress on histone acetylation levels in major depressive disorders
Meng, Y., Du, J., Liu, N., Qiang, Y., Xiao, L., Lan, X., Ma, L., Yang, J.-M., Yu, J., & Lu, G. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2125978 · Cited by 14
Mood phenotypes in rodent models with circadian disturbances
Imamura, K., & Takumi, T. (2022) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2022.100083 · Cited by 11
Yoshimura, Y., Ishikawa, C., Kasegai, H., Masuda, T., Yoshikawa, M., & Shiga, T. (2016) · Neuroscience Research · doi:10.1016/j.neures.2016.09.008 · Cited by 11
Neurobiology of Mood Disorders
Manchia, M., & Schatzberg, A. F. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_83 · Cited by 11
Tafet, G. E., & Alonso, T. O. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1600165 · Cited by 30
Shen, Z., Yu, M., & Dong, Z. (2023) · Medicina · doi:10.3390/medicina59040741 · Cited by 12
Yin, M.-Y., Guo, L., Zhao, L., Zhang, C., Liu, W.-P., Zhang, C.-Y., Huo, J.-H., Wang, L., Li, S., Zheng, C., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02945-0 · Cited by 10
Liu, F., Tian, Q., Tang, H.-L., Cheng, X., Zou, W., & Zhang, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173677 · Cited by 12
MiR-182-5p: A Novel Biomarker in the Treatment of Depression in CSDS-Induced Mice
Zheng, Y.-B., Sheng, X.-M., Jin, X., & Guan, W. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad064 · Cited by 10
“A major cause of depression is considered as a disruption of homeostasis in neurological function in the central nervous system (Duman and Aghajanian, 2012).”
BackgroundDeng, M., Yan, Y.-Z., Zhu, S., Zhou, K., Tan, S.-J., & Zeng, P. H. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073285198240322072301 · Cited by 12
Chen, H., Zhao, X., Ma, X., Ma, H., Zhou, C., Zhang, Y., Peng, Z., Xue, S., & Cai, M. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1388946 · Cited by 12
“Compelling studies demonstrated that esketamine exerts its rapid anti-depressant effects through up-regulated glutaminergic transmission, increased synaptogenesis and neurotrophic factor activity (27 – 30).”
BackgroundFollicle-stimulating hormone induces depression-like phenotype by affecting synaptic function
Huang, L., Sun, S., Jiang, G., Xie, G., Yang, Y., Chen, S., Luo, J., Lv, C., Li, X., Liao, J., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1459858 · Cited by 11
The ketamine chameleon: history, pharmacology, and the contested value of experience
Diep, D., de la Salle, S., Lévesque, J. T., Lifshitz, M., Garel, N., & Greenway, K. T. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2459377 · Cited by 11
“Similar to what has been observed with drugs like propofol, high doses of ketamine can reduce neural complexity (2J) and produce neurotoxicity (2Kii), though the evidence for this is highly dose, time, age, and context dependent [175–177].”
Convergent neurobiological predictors of mood and anxiety symptoms and treatment response
Jabbi, M., & Nemeroff, C. B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1620604 · Cited by 10
Liu, J., & Qi, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28558 · Cited by 13
Xiao, Y., Luo, H., Yang, W. Z., Zeng, Y., Shen, Y., Ni, X.-Y., Shi, Z., Zhong, J., Liang, Z., Fu, X., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00048 · Cited by 11
Advanced maternal age impairs synaptic plasticity in offspring rats
Han, W., Pan, Y. N., Han, Z., Huang, D., Hong, S., Song, X., Cheng, L., & Jiang, L. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113830 · Cited by 10
Jiang, C., Zheng, S., Chen, T., Li, W., Zhang, C., Gu, S., Ren, H., Huanhuan, Song, J., & Zhang, Z. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.09.013 · Cited by 10
Kurauchi, Y., Ohta, Y., Matsuda, K., Sanematsu, W., Devkota, H. P., Seki, T., & Katsuki, H. (2023) · Nutrients · doi:10.3390/nu15030581 · Cited by 12
“Rodent studies also provide evidence of reduced synaptic density and decreased neuronal activity in the PFC region in mice subjected to chronic unpredictable stress (CUS) [24].”
BackgroundArutjunyan, A. V., Milyutina, Y. P., Shcherbitskaia, A. D., Kerkeshko, G. O., & Zalozniaia, I. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923040016 · Cited by 12
“It was found that chronic stress causes reduction in the length and branching of apical dendrites, as well as dysfunction and decrease in the number of synapses on dendritic spines of pyramidal neurons in the medial prefrontal cortex, neurons in the CA3 region of the hippocampus, and granular neurons of the dentate gy…”
BackgroundLin, S., Zhang, C., Zhang, Y., Chen, S., Lin, X., Peng, B., Xu, Z., Hou, G., & Qiu, Y. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.139 · Cited by 10
The neural basis underlying female vulnerability to depressive disorders
Kim, M., Kim, W., & Chung, C. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2276815 · Cited by 15
“The mPFC is a hub region involved in emotional processing and stress responses (Duman and Aghajanian 2012; Hare and Duman 2020; Bittar and Labonte 2021).”
BackgroundNovel agents in development for the treatment of depression
Grady, M. M., & Stahl, S. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000758 · Cited by 11
Mitra, S., Kumar, G. S. S., Lakshmi, B. J., Thakur, S. S., & Kumar, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00133 · Cited by 16
“This was similar to the expression profile of GATA1 as was shown by Kang et al. (2012) for Major Depression in humans.”
BackgroundInfluentialReactive Depression: Lost in Translation!
Showraki, M. (2019) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000989 · Cited by 12
“Glutamate N-methyl-D-aspartate receptor antagonists such as ketamine have been shown since the 1990s to possess properties that can rapidly reverse depressive symptoms (Duman and Aghajanian, 2012; Trullas and Skolnick, 1990).”
BackgroundThe significance of physical activity in the prevention of depressive disorders
Saran, T., Mazur, A., & Łukasiewicz, J. (2020) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/118054 · Cited by 15
Impaired LTD-like motor cortical plasticity in female patients with major depression disorder
Yu, C., Li, A., Li, X., Chen, Z., Wang, P., Dong, Z., Daskalakis, Z. J., & Zhou, D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108268 · Cited by 10
Antidepressant Drug Discovery and Development: Mechanism and Drug Design Based on Small Molecules
Yao, C., Jiang, X., Ye, X., Xie, T., & Bai, R. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200007 · Cited by 10
Fuller, J. J. L., Murray, R. C., & Horner, K. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.023 · Cited by 13
Ogundele, O. M., Okunnuga, A. A., Fabiyi-Edebor, T. D., Olajide, O. J., Akinrinade, I. D., Adeniyi, P. A., & Ojo, A. A. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9447-6 · Cited by 9
“However, the study by Duman and Aghajanian (2012) reveals that NMDA-R antagonists, administered at a low dose, enhances robust and rapid neurogeneration at synaptic endings in adult neurons.”
BackgroundNeurobiological advances identify novel antidepressant targets
Duman, R. S. (2013) · World Psychiatry · doi:10.1002/wps.20058 · Cited by 10
Self-citationKobayashi, Y., & Segi‐Nishida, E. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172767 · Cited by 13
Kowalczyk, J., Nakos‐Bimpos, M., Polissidis, A., Dalla, C., Kokras, N., Skalicka‐Woźniak, K., & Budzyńska, B. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112985 · Cited by 11
Chen, X., Zhang, K., Li, Y., Wang, C., Lou, H., & Yu, S. Y. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03314-4 · Cited by 19
“Synaptic elimination represents an important process for the formation of appropriate/normal neural circuits and is crucial for brain development and maintenance of neuronal homeostasis in depression [64, 65].”
Wang, G., Yang, H., Zuo, W., & Mei, X. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000713 · Cited by 9
“Ketamine, an N-methyl-D-aspartic acid receptor (NMDAR) antagonist, has shown rapid antidepressant effects in both patients and animal models (Duman and Aghajanian, 2012) and esketamine has been approved by the U.”
BackgroundLi, C., Zhang, J., Liu, H., Yuan, H., Cai, J., Fogaça, M. V., & Zhang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115137 · Cited by 8
Li, B., Lin, Y., Ren, C., Cheng, J., Zhang, Y., & Han, S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.076 · Cited by 10
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 15
“Intravenous ketamine therapy for depression has been argued to be the most vital breakthrough in the psychiatry field since the 1950s [7].”
BackgroundmiR-143-3p modulates depressive-like behaviors via Lasp1 in the mouse ventral hippocampus
Yu, H., Li, X., Zhang, Q., Geng, L., Su, B., & Wang, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06639-y · Cited by 12
“In both patients with depression and animal models of depression, a reduction in dendritic spine density and alterations in their morphology is associated with depression 17,18 .”
BackgroundPsychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 12
Naughton, S. X., Yang, E.-J., Iqbal, U. H., Trageser, K. J., Charytonowicz, D., Masieri, S., Estill, M. S., Wu, H. D., Raval, U., Lyu, W., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03215-3 · Cited by 11
Han, X., Fu, X., Guo, W., Liu, Y., Sun, J., Wang, T., & Yang, W. (2024) · Inflammation · doi:10.1007/s10753-024-02190-4 · Cited by 11
“At the molecular level, depression is characterized by impaired neuroplasticity, including neuronal atrophy and synaptic inhibition in the PFC and hippocampus [3, 4].”
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity
Olson, D. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231054 · Cited by 13
Yan, C., Zheng, W., Du, Y., Li, Y., Wang, M., & Qu, M. (2025) · Nature and Science of Sleep · doi:10.2147/nss.s491714 · Cited by 13
“50,51 Furthermore, sleep disorders may act as a risk factor for the onset of depression by impairing the processing of emotional memories.”
Therapeutic implications for NMDA receptors in mood disorders
Hashimoto, K. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811894 · Cited by 10
Antidepressant effects of acupuncture in a murine model: regulation of neurotrophic factors
Yamamoto, T., Kawanokuchi, J., Nagaoka, N., Takagi, K., Ishida, T., Hayashi, T., & Ma, N. (2022) · Acupuncture in Medicine · doi:10.1177/09645284221085279 · Cited by 11
Liu, C., Shi, R., Liu, Y., Zhao, X., Zhang, X., Wang, H., Wu, L., & Shang, X. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114366 · Cited by 9
Dysfunction of GluN3A subunit is involved in depression-like behaviors through synaptic deficits
Zhang, M., Kong, X., Chen, J., Liu, W., Liu, C., Dou, X., Jiang, L. H., Luo, Y., Song, M., Miao, P., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.076 · Cited by 11
Yang, S., Yi, L., Xia, X., Chen, X., Hou, X., Zhang, L., Yang, F. Y., Liao, J., Han, Z., & Fu, Y. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.074 · Cited by 10
The role of cell adhesion molecule IgSF9b at the inhibitory synapse and psychiatric disease
Clarin, J. D., Reddy, N., Alexandropoulos, C., & Gao, W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105476 · Cited by 10
Targeting Nr2e3 to Modulate Tet2 Expression: Therapeutic Potential for Depression Treatment
Ma, X., Xu, S. S., Zhou, Y., Zhang, Q., Yang, H., Wan, B., Yang, Y., Miao, Z., & Xu, X. (2024) · Advanced Science · doi:10.1002/advs.202400726 · Cited by 10
Glycine Transporter-I Inhibitors: A New Class of Antidepressant?
Mathew, S. J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.019 · Cited by 9
Impaired fear memory extinction during adolescence is accompanied by the depressive-like behaviors
Lu, K., Jing, X., Xue, Q., Song, X.-J., Wei, M.-D., & Wang, A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.039 · Cited by 11
Peng, Y., Su, Y., & Jiang, Y. (2020) · Technology and Health Care · doi:10.3233/thc-209024 · Cited by 10
“It is reported that depression is closely associated with changes in brain structure that regulate mood and cognitive function [13].”
BackgroundSu, F., Wei, M., Sun, M., Jiang, L., Dong, Z., Wang, J., & Zhang, C. (2022) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2022.109750 · Cited by 10
Aligeti, S., Quinones, M. P., & Salazar, R. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000146 · Cited by 9
Treating the Brain Deep Down: Short-circuiting depression
Warner‐Schmidt, J. L. (2013) · Nature Medicine · doi:10.1038/nm.3215 · Cited by 12
(2018) · Europe PMC (PubMed Central)
Self-citationKetamine in depression and electroconvulsive therapy
Rozet, I. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001039 · Cited by 10
“These findings lead to the development of a novel neurotrophic, or plasticity-related, concept of depression [21].”
BackgroundLinking Omega-3 Fatty Acids and Depression
Godos, J., Castellano, S., Galvano, F., & Grosso, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815238-6.00013-4 · Cited by 13
Bartova, L., Lanzenberger, R. R., Rujescu, D., & Kasper, S. F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02093-0 · Cited by 15
“…serotonergic neurotransmission, that was originally introduced by the English psychiatrist Alec Coppen in 1967 [1], has been increasingly ampli fi ed by groundbreaking insights on neurobiological mechanisms involving further crucial monoaminergic, glutamatergic, GABAergic and other systems [2, 3].”
BackgroundSun, H. G., Bai, T., Zhang, X., Fan, X., Zhang, K., Zhang, J., Hu, Q., Xu, J., Tian, Y., & Wang, K. (2024) · Brain Imaging and Behavior · doi:10.1007/s11682-024-00884-9 · Cited by 8
“One possible explanation is that this pathway influences synaptic maturation and stability in depression (Duman & Aghajanian, 2012), whereas ECS (Chen et al., 2018), even a single administration (Chen et al., 2020), could significantly increase number of synapses.”
Liu, H., Chen, S., Hong, X., Xiao, J., Zhao, S., Zhang, X., Shu, Z., Zhang, J., Ouyang, J., Liu, Q., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111256 · Cited by 8
Hippocampal Zkscan4 confers resilience to chronic stress–induced depression-like behaviors
Gao, K., Yang, Y., Sun, X., Wang, J., Sun, X., Lu, T., Wang, L., Li, M., Yue, W., Liu, H., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2291 · Cited by 10
“Moreover, a growing body of evidence has indicated that dysfunction of synaptic transmission, especially excitatory synaptic transmission, may be associated with the pathophysiology of depression ( 40 , 41 ).”
Mikellides, G. (2025) · Psychoactives · doi:10.3390/psychoactives4030020 · Cited by 9
“Ketamine and esketamine promote rapid neuroplasticity by increasing synaptoge-nesis and restoring functional connectivity in brain regions critically involved in mood regulation, such as the prefrontal cortex, hippocampus, and anterior cingulate cortex [7].”
Singanwad, P., Tatode, A., Qutub, M., Taksande, B. G., Umekar, M. J., Trivedi, R., & Premchandani, T. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102538 · Cited by 9
Shared Mechanisms in Dementia and Depression: The Modulatory Role of Physical Exercise
de Souza, P. B., Rodrigues, A. L. S., & Felice, F. G. D. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70185 · Cited by 15
“Protocols involving chronic stress or corticosterone/GC treatment in rodents have demonstrated a decrease in neurogenesis and gliogenesis, deficits in cell proliferation and differentiation, and cell survival in the hippocampus (Duman and Aghajanian 2012; Leschik et al. 2021).”
Li, Y., Ma, J., Zhang, W., Cao, Y.-L., & Chen, L. (2025) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v53i4.1967 · Cited by 10
Antidepressants and the endogenous opioid system
Fricker, L. D., Osman, A., Gupta, A., Gomes, I., & Devi, L. A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117392 · Cited by 12
Takahashi, M., & Shelton, R. C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1666599 · Cited by 18
“Neurons often show signs of atrophy rather than a reduction in number in the dorsolateral PFC (dlPFC) and hippocampus of individuals with MDD (97, 108).”
InfluentialFrom Fat to Brain: Adiponectin as a Mediator of Neuroplasticity in Depression
Genini, P., D’Aprile, I., Petrillo, G., Benedetto, M. G. D., Begni, V., Cattane, N., & Cattaneo, A. (2025) · Biomolecules · doi:10.3390/biom15121642 · Cited by 9
“…LTP and long-term depression (LTD) are also fundamental for hippocampal function, particularly in enabling memory formation, learning, and the integration of newly generated neurons into existing circuits [43] and in supporting the adaptive integration of new neurons into existing circuits [44,45].”
Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments
O’Donnell, P., Etkin, A., & Manji, H. K. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251212 · Cited by 9
Bao, C., Wang, Y., Le, T. T., Xu, L., Tang, W., Zou, W., Bao, Y., Xu, D., & Zhao, K. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04976-6 · Cited by 12
“At the neurocognitive and molecular level, depression is currently described as a disorder of impaired cognitive flexibility and a failure of neuroplasticity [49, 50], including neuronal atrophy and synaptic inhibition in the medial prefrontal cortex and hippocampus [51, 52].”
BackgroundLi, Y., Chen, X., Lan, T., Wang, W., Wang, C., Chang, M., Yu, Z., & Yu, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132854 · Cited by 12
Chronic unpredictable stress induces autophagic death of adult hippocampal neural stem cells
Choe, S., Jeong, H., Choi, J., & Yu, S. (2024) · Molecular Brain · doi:10.1186/s13041-024-01105-6 · Cited by 10
“Current treatments for depression and stress-related neurological disorders requires long-term medication and are not effective for all patients, and some patients may have drug resistance or experience side effects [13].”
BackgroundMulti-target Therapy for Subcellular Incompatibility in Brain Disorders
Wang, J., & Cui, S. (2015) · Brain Disorders & Therapy · doi:10.4172/2168-975x.1000200 · Cited by 8
Novel Therapeutic Targets for Major Depressive Disorder
Lazar, M. A., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00034-2 · Cited by 10
Subanesthetic ketamine exerts antidepressant-like effects in adult rats exposed to juvenile stress
Aikawa, K., Yoshida, T., Ohmura, Y., Lyttle, K. A., Yoshioka, M., & Morimoto, Y. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146980 · Cited by 8
Lamontagne, S. J., Ballard, E. D., & Zarate, C. A. (2022) · Neurobiology of Stress · doi:10.1016/j.ynstr.2022.100450 · Cited by 12
Salari, M., Eftekhar‐Vaghefi, S. H., Asadi‐Shekaari, M., Esmaeilpour, K., Solhjou, S., Amiri, M., & Ahmadi‐Zeidabadi, M. (2023) · Brain and Behavior · doi:10.1002/brb3.2986 · Cited by 8
“The discovery of the fast and potent effects of ketamine has been praised as “arguably the most important discovery [in neuropsychiatric research] in half a century” (Duman & Aghajanian, 2012).”
BackgroundPlasticity-augmented psychotherapy for refractory depressive and anxiety disorders
Choi, K., & Kim, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.003 · Cited by 8
Stylianakis, A. A., Harmon‐Jones, S. K., Richardson, R., & Baker, K. (2018) · Developmental Psychobiology · doi:10.1002/dev.21750 · Cited by 13
“…exposure to such hormones leads to neural and psycholog‐ ical dysfunction in both adults and adolescents (Belanoff, Gross, Yager, & Schatzberg, 2001; Duman & Aghajanian, 2012; Lupien, McEwen, Gunnar, & Heim, 2009; McEwen, 2004; Vyas, Mitra, Shankaranarayana School of Psychology, UNSW Sydney,…”
Background[Laboratory diagnosis of autoimmune thyroid disease].
Tozzoli, R., Villalta, D., Bizzaro, N., Tonutti, E., & Manoni, F. (2001) · PubMed · Cited by 9
Insights from a methylome-wide association study of antidepressant exposure
Davyson, E., Shen, X., Huider, F., Adams, M. J., Borges, K., McCartney, D. L., Barker, L., van Dongen, J., Boomsma, D. I., Weihs, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55356-x · Cited by 12
“Another prominent theory suggests that antidepressants exert their therapeutic effects by increasing brain-derived neurotrophic factor (BDNF), leading to synaptic remodelling 13 and enhanced neuronal plasticity 8,14 .”
InfluentialXanthouhumol relieves stress-induced depressive-like behaviors through the Sirt1/NF-κB/NLRP3 pathway
Lin, G., Zhang, Y., Qin, J., He, Y., Fan, L., Tan, Q., & Xie, P. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06819-6 · Cited by 10
“Depression is closely associated with synaptic dysfunction (Duman and Aghajanian 2012), particularly in the medial prefrontal cortex (mPFC), a brain region essential for mood regulation, cognition, and decision-making (Price and Duman 2020).”
Xu, C., Liu, J., Guo, M., Wang, J., Bai, X., Zhang, C., Luan, X., Pei, H., Liu, H., Lv, X., et al. (2025) · Research · doi:10.34133/research.0746 · Cited by 13
“Clinical investigations have revealed a significant reduction in GABA levels in the cerebro-spinal fluid and cerebral cortex of depressed patients [ 21 ], which coincides with impaired synaptic function [ 22 ].”
Gualtieri, G., Cuomo, A., Pardossi, S., & Fagiolini, A. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113858 · Cited by 11
“Finally, long-term SSRI treatment induces adaptive neuroplastic changes including the downregulation of postsynaptic 5-HT receptors and changes in intracellular signaling cascades, possibly critical for their therapeutic mechanisms in obsessive–compulsive disorder [25].”
Yu, D.-Y., Gao, J.-Q., Yang, X.-X., Gao, F.-F., Liu, J., Shen, M.-Q., Gu, B., Zhang, Y.-X., & Yan, C. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110579 · Cited by 7
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
New advances in small molecule drugs targeting NMDA receptors
Zeng, Y., Qu, Z.-Y., Zhu, Q., Wang, H., Zhou, Y., & Gao, Z.-B. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01675-8 · Cited by 9
“This fi nding was subsequently replicated and extended [100 – 108], and they spurred extensive research into glutamatergic mechanisms of depression and NMDA receptor-targeted therapeutic strategies [109 – 113].”
Li, Y., Han, S., Xie, T., Song, K., Zeng, W., Wang, H., Hu, C., Zhang, Z., Hashimoto, K., Ma, L., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178468 · Cited by 7
Cortical Mechanisms Contributing to Ketamine-Induced Dissociation
Bera, K., Looger, L. L., Proekt, A., & Cichon, J. (2025) · The Neuroscientist · doi:10.1177/10738584251403946 · Cited by 10
“An additional critical contributor to ketamine’s cortical actions is its effect on hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, which regulate neuronal excitability and rhythmic activity (Magee 1998; Chen et al 2009; Wahl-Schott and Biel 2009; Duman and Aghajanian 2012).”
Raffone, F., Mazzoni, F., Ciechi, A. D., Girone, N., Macellaro, M., Martinotti, G., Dell’Osso, B. M., Olivola, M., & Martiadis, V. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104983 · Cited by 10
Zhang, K., Chang, Q., Li, F., Li, Y., Ding, R., & Yu, Y. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14406 · Cited by 10
“35,36 Consistent with previous evidence, our results displayed that CSDS led to decreased dendritic complexity and spine density, the sEPSC frequency, and amplitude of dCA1 pyramidal neurons in adult mice with surgery/sevoflurane.”
ResultSumner, R. L., McMillan, R. L., Forsyth, A., Muthukumaraswamy, S. D., & Shaw, A. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02738-w · Cited by 13
Xu, J.-J., Kan, W., Wang, T., Li, L., Zhang, Y., Ge, Z.-Y., Xu, J.-Y., Yin, Z.-J., Feng, Y., Wang, G., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.038 · Cited by 8
CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function
Hu, N., Zheng, Y., Liu, X., Jia, J., Feng, J., Zhang, C., Liu, L., & Wang, X. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04420-0 · Cited by 8
Zou, Z., Xiao, N., Chen, Z., Lin, X., Li, Y., Li, P., Cheng, Q., & Du, B. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300467 · Cited by 9
Wu, Z., Yin, Y., Liu, R., Li, X., Wang, Z., Wu, C., Tan, J., Fu, Z., Song, C., Wong, N. L., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119031 · Cited by 10
Wu, C. Y., Zhang, Y., Howard, P., Huang, F., & Lee, R. H. (2024) · GeroScience · doi:10.1007/s11357-024-01424-5 · Cited by 8
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.